SCHEMBL10186673

SCHEMBL10186673

CCCc1ccc(Cl)c(CNCC2CCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TP53 P04637 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
CXCR4 P61073 13/20 0.42
SIGMAR1 Q99720 2/20 0.39
EBP Q15125 1/20 0.39
HDAC6 Q9UBN7 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10186664 0.94 MEN1 (0.55) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL661726 0.86 MEN1 (0.46) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL10186685 0.81 HTR1A (0.42) MEN1KMT2ACYP3A4CYP2D6CYP2C9
SCHEMBL10186681 0.81 POLB (0.45) MEN1KMT2ACYP3A4CYP2D6CYP2C19
SCHEMBL664699 0.80 MEN1 (0.51) MEN1KMT2ATP53CYP3A4CYP2D6
SCHEMBL10186620 0.77 POLB (0.41) MEN1KMT2ACYP3A4CYP2D6CYP2C19
SCHEMBL10186666 0.75 SLC6A4 (0.51) SIGMAR1
SCHEMBL10186676 0.74 LMNA (0.39) MEN1KMT2ASIGMAR1
SCHEMBL10186682 0.73 SIGMAR1 (0.36) MEN1KMT2ACYP3A4CYP2C19SIGMAR1
SCHEMBL3093517 0.72 PRMT5 (0.55) MEN1KMT2ATP53CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046293-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046293-A1 RENIN INHIBITORS REN, ACE, AGTR1 MEN1 3395/4885KMT2A 4587/4885TP53 4790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.